Her2 conference...It never hurts to see what the researchers are talking about
 

<TABLE cellSpacing=0 cellPadding=0 width=600 align=center border=0><TBODY><TR><TD>If you are unable to view the graphics, click here to view e-mail online

</TD></TR></TBODY></TABLE><TABLE cellSpacing=0 cellPadding=0 width=600 align=center background=http://cancerconferences.com/HTML_email/Breast/paradigmsbc_0607/bg.gif border=0><TBODY><TR><TD>http://www.cancerconference.com/HTML...7/masthead.jpg</TD></TR><TR><TD vAlign=top><TABLE cellSpacing=0 cellPadding=2 width=580 align=center border=0><TBODY><TR><TD vAlign=top>
Chairs:
Mark Pegram, MD
Los Angeles, CA

Michael Untch, MD, PhD
Berlin, Germany


<TABLE cellSpacing=0 cellPadding=0 width=575 align=center border=0><TBODY><TR><TD class=body1 vAlign=top width=70> </TD><TD class=body1 vAlign=top width=293>Agenda</TD><TD class=body1 vAlign=top width=12> </TD><TD class=body1 vAlign=top width=200>Faculty

View Complete Faculty Details</TD></TR><TR><TD class=body1 vAlign=top> </TD><TD class=body1 vAlign=top> </TD><TD class=body1 vAlign=top> </TD><TD class=body1 vAlign=top> </TD></TR><TR bgColor=#f5f0d9><TD class=body1 vAlign=top width=70 bgColor=#f5f0d9>1:00 pm</TD><TD class=body1 vAlign=top width=293 bgColor=#f5f0d9>Registration and Reception

</TD><TD class=body1 vAlign=top width=12> </TD><TD class=body1 vAlign=top width=200>

</TD></TR><TR><TD class=body1 vAlign=top width=70>1:30 pm</TD><TD class=body1 vAlign=top width=293>Welcome and Overview

</TD><TD class=body1 vAlign=top width=12> </TD><TD class=body1 vAlign=top width=200>

</TD></TR><TR bgColor=#f5f0d9><TD class=body1 vAlign=top width=70>1:35 pm</TD><TD class=body1 vAlign=top width=293>Targeting HER2 in Early Breast Cancer: Progress in Individualizing Therapy

</TD><TD class=body1 vAlign=top width=12> </TD><TD class=body1 vAlign=top width=200>Edward Romond, MD
Lexington, KY

</TD></TR><TR><TD class=body1 vAlign=top width=70>1:55 pm</TD><TD class=body1 vAlign=top width=293>Novel Approaches to HER2-Positive Breast Cancer: Emerging Targeted Agents

</TD><TD class=body1 vAlign=top width=12> </TD><TD class=body1 vAlign=top width=200>Mark Pegram, MD
Los Angeles, CA

</TD></TR><TR bgColor=#f5f0d9><TD class=body1 vAlign=top width=70>2:15 pm</TD><TD class=body1 vAlign=top width=293>Practical Considerations for Angiogenesis Inhibition in Advanced Breast Cancer

</TD><TD class=body1 vAlign=top width=12> </TD><TD class=body1 vAlign=top width=200>Ruth O’Regan, MD
Atlanta, GA

</TD></TR><TR><TD class=body1 vAlign=top width=70>2:35 pm</TD><TD class=body1 vAlign=top width=293>Multiplying the Benefits: Novel Combinations of Targeted Agents

</TD><TD class=body1 vAlign=top width=12> </TD><TD class=body1 vAlign=top width=200>Michael Untch, MD, PhD
Berlin, Germany

</TD></TR><TR bgColor=#f5f0d9><TD class=body1 vAlign=top width=70>2:55 pm</TD><TD class=body1 vAlign=top width=293>Cooperative Mutations: Potential Contributions of c-MYC Amplification and Other Genetic Alterations in HER2-Positive Breast Cancer

</TD><TD class=body1 vAlign=top width=12> </TD><TD class=body1 vAlign=top width=200>Soonmyoung Paik, MD
Pittsburgh, PA

</TD></TR><TR><TD class=body1 vAlign=top width=70>3:15 pm</TD><TD class=body1 vAlign=top width=293>Question-and-Answer Session

</TD><TD class=body1 vAlign=top width=12> </TD><TD class=body1 vAlign=top width=200>

</TD></TR><TR bgColor=#f5f0d9><TD class=body1 vAlign=top width=70>3:30 pm</TD><TD class=body1 vAlign=top width=293>Adjourn

</TD><TD class=body1 vAlign=top width=12> </TD><TD class=body1 vAlign=top width=200>

</TD></TR></TBODY></TABLE>
<HR SIZE=1>Program Overview

The New Paradigms in the Biologic Therapy of Breast Cancer: Translating Advances in Molecular Biology Into Improved Patient Outcomes satellite symposium will educate physicians on the latest advances in biologic therapies for breast cancer, with a focus on HER2<SUP>+</SUP> disease. One lecture will be devoted to the potential for optimizing and individualizing HER2-targeted therapy for early-stage breast cancer, while a second will explore new agents targeting this pathway in metastatic disease. A third lecture will focus on the use of angiogenesis inhibitors. Two additional lectures will review activation pathways or genomic mutations, respectively, that cooperate with HER2 signaling in neoplasia and therapy combination strategies aimed at preventing the emergence of resistance via activation of alternate growth or survival signals.

This presentation was selected by the American Society of Clinical Oncology<SUP>®</SUP> as an independent educational activity held in conjunction with an ASCO<SUP>®</SUP> meeting. This presentation is not sponsored or endorsed by ASCO.

<HR SIZE=1>Educational Objectives

At the conclusion of this meeting, you should be able to:

• <LI class=body1>Review results from adjuvant trials targeting HER2<SUP>+</SUP> breast cancer and the potential for individualizing therapy based on genomics or other risk factors <LI class=body1>Summarize novel therapeutic approaches to targeting HER2 in breast cancer, including small-molecule tyrosine kinase inhibitors, dimerization inhibitors, antibody-toxin conjugates, and HSP90 inhibitors <LI class=body1>Assess the utility of angiogenesis inhibition in the treatment of metastatic breast cancer, and list agents undergoing clinical investigation <LI class=body1>Explain the rationale underlying combinations of novel targeted agents, including combinations of HER2-targeted agents with angiogenesis inhibitors, endocrine therapy, and mTOR inhibitors
• Describe other signaling pathways that might interact with HER2 receptor signaling and the ways that mutations in these pathways might cooperate in the process of oncogenic transformation

<HR SIZE=1>CME Accreditation

Physicians’ Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians’ Education Resource designates this educational activity for a maximum of 2 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

<HR SIZE=1>Venue

Sheraton Chicago Hotel & Towers
Sheraton Ballroom 4-5
301 E. North Water St.
Chicago, IL 60611
Phone: (312) 464-1000

<HR SIZE=1>Registration

To view registration information please Click Here

If you are unable to access the above link, copy and paste the following link into the address bar of your broswer: http://paradigmsbc.cancerconferences.com/registration.php

<HR SIZE=1>View More

For more information regarding this free CME meeting please Click Here

</TD></TR></TBODY></TABLE></TD></TR><TR><TD><TABLE cellSpacing=0 cellPadding=0 width=537 align=center border=0><TBODY><TR><TD>This activity is supported by an educational grant from Genentech BioOncology.

http://cancerconferences.com/HTML_em...07/PERlogo.gif

Physicians' Education Resource | 3500 Maple Ave., Suite 700 | Dallas, TX 75219


</TD></TR></TBODY></TABLE></TD></TR></TBODY></TABLE>

Another given during the ASCO Conference

I forwarded this on to my onc... I know he can't go since he and wife are expecting at that time, and I bet he already knows about the conf, but I just want him to know I am on top of it too, thanks to the ladies here at Her2Support!